Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Dividend Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Eliem Therapeutics Inc Dividend Coverage Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The dividend coverage ratio measures a company's ability to cover its dividend payments with its net income. It is calculated by dividing net income by dividends paid. This ratio indicates the proportion of net income that is allocated to paying dividends. A ratio greater than 1 suggests sufficient income to cover dividend payments, while a ratio less than 1 indicates a potential shortfall.
  • Eliem Therapeutics Inc Dividend Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -7.63, a -138.86% change year over year.
  • Eliem Therapeutics Inc Dividend Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -3.20.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email